Background: Insulin is widely used in the treatment of diabetes. There is an increasing concern regarding the association between insulin glargine use and breast cancer.
Aim: To systematically review the literature on insulin glargine use and breast cancer risk.
Methods: A systematic literature search on the relevant articles assessing insulin glargine use and breast cancer during the period from January 2008 to January 2018 was carried out. Studies on animals, human cell line, and humans, in English language that state the duration and dose of insulin glargine use, and the number of participants were retrieved from MEDLINE, Web Of Science, EMBASE, PubMed, and EBSCO, using the keywords insulin glargine, insulin Lantus, insulin analogs, breast neoplasia, and breast cancer. 
Results: Out of 311 articles, 34 manuscripts stand after duplication removal and applying the inclusion and exclusion criteria (twelve experimental studies, eight reviews, and fourteen human studies). The  reviews’ results were inconclusive, human studies showed no relation of insulin glargine with breast cancer except at high dose and long duration of ≥ five years, and prior human insulin use, while the experimental studies showed a decreased breast cancer latency. 
Conclusion: There is no association between insulin glargine and breast cancer. Some of the studies showed an association with a long duration of high doses and prior human insulin use. Treating physicians may need to use insulin glargine as the basal insulin of choice before human insulin, although the dose and duration need to be taken into consideration. Real-world studies are needed.
Keywords: Insulin glargine, Dose, and duration, Breast cancer


» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/7408
This study has followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (http://www.prisma-statement.org). PRISMA is an evidence-based minimum set of items for reporting in systematic reviews and meta-analyses. PRISMA focuses on the reporting of reviews evaluating randomized trials, but can also be used as a basis for reporting systematic reviews of other types of research, particularly evaluations of interventions.



The  most recent editorial (June 2021)

Ethics of Publishing Case Reports: Do We Need Ethics Approval and Patient Consent?

An editorial by Dr. Mehrdad Jalalian

Read more.

The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.


To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here


Our previous editorial (June 2020)

Lessons from COVID-19 pandemic and the Morocco’s success story.

An editorial by Dr. Benksim Abdelhafid (Morocco)

Read more.


The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:


TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:

Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: